<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984837</url>
  </required_header>
  <id_info>
    <org_study_id>KILT</org_study_id>
    <nct_id>NCT04984837</nct_id>
  </id_info>
  <brief_title>Study of Lacutamab in Peripheral T-cell Lymphoma</brief_title>
  <official_title>A Randomized Non Comparative Phase II Study of Lacutamab With GemOx Versus GemOx Alone in Relapsed/Refractory Patients With Peripheral T-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innate Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label multicenter randomized non comparative phase II study to evaluate the&#xD;
      safety and efficacy of the monoclonal anti-KIR3DL2 antibody Lacutamab in patients with&#xD;
      Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other&#xD;
      Specified (NOS), PTCL-TFH (including Angioimmunoblastic T-cell Lymphoma (AITL), Follicular&#xD;
      T-cell lymphoma, Nodal peripheral T-cell lymphoma with TFH phenotype), Anaplastic large cell&#xD;
      lymphoma (ALCL), Adult T-cell leukemia/lymphoma (ATL), Hepatosplenic T-cell lymphoma (HSTL),&#xD;
      Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T cell&#xD;
      lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL).&#xD;
&#xD;
      The design is non comparative meaning that non comparison between arms will be performed as&#xD;
      the control arm will ensure that the assumptions used for sample size calculation are&#xD;
      verified. For that reason, randomization is unbalanced in favor of the experimental arm&#xD;
      (2:1).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median modified progression-free survival (mPFS) - CT-based</measure>
    <time_frame>5,5 years.</time_frame>
    <description>time from randomization until one of the following events occurs, whichever comes first:&#xD;
Disease progression (PD)&#xD;
Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT))&#xD;
Relapse after achievement of CR&#xD;
Death due to any cause. PD and relapse will be evaluated according to Lugano 2014 criteria (CT-based).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>median modified progression-free survival (mPFS) - PET-based</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rate (CRR) Lugano 2014 criteria (CT-based)</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete response rate (CRR) Lugano 2014 criteria (PET-based)</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR) Lugano 2014 criteria (CT-based)</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR) Lugano 2014 criteria (PET-based)</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate assessed by Deauville criteria</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR),</measure>
    <time_frame>5,5 years.</time_frame>
    <description>Disease progression (PD)&#xD;
Administration of any additional unplanned anti-lymphoma treatment (except allogeneic or autologous hematopoietic cell transplantations (HCT))&#xD;
Relapse after achievement of CR&#xD;
Death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of patients proceeding to allogenic stem cell transplantation</measure>
    <time_frame>5,5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>1 month (1 cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>1 month (1 cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>2 months (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>2 months (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>3 months (3 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>3 months (3 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>7 months (7 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>7 months (7 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>9 months (9 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>9 months (9 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>15 months (15 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>15 months (15 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>26 months (26 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>26 months (26 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Maximal Concentration of lacutamab (Cmax)</measure>
    <time_frame>29 months (29 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of lacutamab with GemOx : Trough Concentration of lacutamab (Ctrough)</measure>
    <time_frame>29 months (29 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>1 month (1 cycle)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>2 months (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>3 months (3 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>7 months (7 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>9 months (9 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>15 months (15 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity : concentration of Anti-Drug Antibodies (ADA)) of lacutamab with GemOx</measure>
    <time_frame>29 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Relapse/Recurrence</condition>
  <arm_group>
    <arm_group_label>Lacutamab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacutamab</intervention_name>
    <description>750 mg/IV</description>
    <arm_group_label>Lacutamab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m²</description>
    <arm_group_label>Lacutamab</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatine</intervention_name>
    <description>100 mg/m²</description>
    <arm_group_label>Lacutamab</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. KIR3DL2-positive with at least 1% of tumour cells positivity, before randomization,&#xD;
             based on central evaluation by immunohistochemistry (IHC) 2. Patients with&#xD;
             histologically documented PTCL:&#xD;
&#xD;
               -  Biopsy-proven treated PTCL defined by the WHO 2016 criteria (the biopsy at&#xD;
                  relapse is recommended but not mandatory):&#xD;
&#xD;
                    -  PTCL-NOS&#xD;
&#xD;
                    -  PTCL-TFH (AITL, Follicular T-cell lymphoma, Nodal peripheral T-cell lymphoma&#xD;
                       with TFH phenotype)&#xD;
&#xD;
                    -  ALCL&#xD;
&#xD;
                    -  ATL: acute- or lymphoma-type&#xD;
&#xD;
                    -  HSTL&#xD;
&#xD;
                    -  EATL&#xD;
&#xD;
                    -  MEITL&#xD;
&#xD;
                    -  NKT&#xD;
&#xD;
                    -  ANKL 3. For patients with ALCL: previously treated with brentuximab vedotin&#xD;
                       4. Relapsed/refractory PTCL after at least one previous line of systemic&#xD;
                       based regimen of chemotherapy (no mandatory latency after the previous&#xD;
                       treatment) 5. With a maximum of 2 prior lines of systemic therapies,&#xD;
                       including autologous stem cell transplantation (ASCT is authorized in first&#xD;
                       and second line and is not counted as a unique line, even if associated to a&#xD;
                       systemic therapy) 6. Bi-dimensionally measurable disease defined by at least&#xD;
                       one single node or tumor lesion ≥ 1.5 cm assessed by CT scan 7. Signed&#xD;
                       written screening informed consent prior to KIR3DL2 screening 8. Signed&#xD;
                       written study informed consent prior to randomization 9. Aged 18 years or&#xD;
                       more with no upper age limit, at randomization 10. Eastern Cooperative&#xD;
                       Oncology Group (ECOG) performance status 0 to 3 prior to prephase treatment&#xD;
                       (if applicable), and 0 to 2 prior randomization 11. Minimum life expectancy&#xD;
                       of 3 months 12. Females of childbearing potential (FCBP) must agree to use&#xD;
                       highly effective contraceptive method* from C1D1, during the entire study&#xD;
                       period, during dose interruptions, and for 9 months after the last study&#xD;
                       treatments 13. FCBP must have a negative serum or urinary pregnancy test&#xD;
                       within 28 days prior C1D1 14. Male patients and their partner (FCBP) must&#xD;
                       agree to use two reliable forms of contraception (condom for males and&#xD;
                       hormonal method for partners) from C1D1, during the entire study period,&#xD;
                       during dose interruptions, and for 9 months after the last study treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with active COVID-19 infection (last positive PCR &lt; 2 weeks before&#xD;
             randomization) 2. Patients taking immunotherapy or chemotherapy, except short-term&#xD;
             corticosteroids in monotherapy at a cumulated dose equivalent of prednisone ≤&#xD;
             1mg/kg/day, during 7 consecutive days, within 3 weeks prior to first administration of&#xD;
             study drug (C1D1); or prephase treatment given at investigator's discretion before&#xD;
             randomization and for maximum 3 weeks (glucocorticosteroids, vepesid (VP16),&#xD;
             cyclophosphamide, vincristine and prednisone (COP)) 3. Previous treatment by&#xD;
             Gemcitabine or Oxaliplatin 4. Use of any experimental anti-cancer drug therapy within&#xD;
             6 weeks before randomization 5. Contraindication to any drug contained in the study&#xD;
             treatment regimen 6. Previous allogenic hematopoietic cell transplantation 7. Positive&#xD;
             test results for HIV and Hepatitis C Virus (HCV) (Patients who are positive for HCV&#xD;
             antibody must be negative for HCV by PCR to be eligible for study participation) 8.&#xD;
             Known active hepatitis B (positive Ag HBs) (if latent Hepatitis B Virus (HBV)&#xD;
             (positive anti-HBc), patients have to be treated with Entecavir (Baraclude ®) and HBV&#xD;
             PCR should be performed every month to allow antiviral strategy adaptation) 9. Central&#xD;
             nervous system or meningeal involvement by lymphoma 10. Any of the following&#xD;
             laboratory abnormalities prior randomization:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &lt; 1 G/L, unless neutropenia is related to PTCL&#xD;
&#xD;
               -  Platelet count &lt; 75 G/L, unless thrombopenia is related to PTCL&#xD;
&#xD;
               -  Alkaline Phosphatases &gt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum Glutamoyl-oxaloacetate Transferase (SGOT) /Alanine aminotransferase (AST)&#xD;
                  or Serum Glutamate Pyruvate Transaminase (SGPT)/Alanine aminotransferase (ALT) &gt;&#xD;
                  2.5 x ULN&#xD;
&#xD;
               -  Bilirubin &gt; 1.5 x ULN, unless SGOT/AST and SGPT/ALT &gt; 2.5 x ULN or bilirubin&#xD;
                  elevated due to PTCL or hemolysis&#xD;
&#xD;
               -  Calculated creatinine clearance (MDRD or Cockcroft) &lt; 40 mL/min 11. Any&#xD;
                  significant cardiovascular impairment: New York Heart Association (NYHA) Class&#xD;
                  III or IV cardiac disease, uncontrolled high blood pressure, unstable angina,&#xD;
                  myocardial infarction or stroke within the last 6 months from randomization, and&#xD;
                  cardiac arrhythmia within the last 3 months from randomization 12. Uncontrolled&#xD;
                  clinically significant intercurrent illness including, but not limited to,&#xD;
                  diabetes, ongoing active infections. Patients receiving antibiotics for&#xD;
                  infections that are under control may be included in the study 13. Concurrent&#xD;
                  malignancy or prior history of malignancies other than lymphoma unless the&#xD;
                  subject has been free of disease for ≥ 2 years, except early stage cutaneous&#xD;
                  squamous or basal cell carcinoma, localized prostate cancer, or cervical&#xD;
                  intraepithelial neoplasia 14. Major surgery within 4 weeks before randomization&#xD;
                  15. Pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morgane Cheminant</last_name>
    <role>Study Chair</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Assemat</last_name>
    <phone>+33(0)272669333</phone>
    <email>kilt@lysarc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Karolien BEEL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A. Z. Sint-Jan</name>
      <address>
        <city>Bruges</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvia SNAUWAERT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire Saint LUC</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarah Bailly, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires de Bruxelles - Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Alice WOLFROMM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Kirsten SAEVELS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Christine NGIRABACU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe Bonnet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ghandi DAMAJ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre MOREL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH d Avignon - Hopital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Borhane SLAMA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Baptiste PERARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon - Hôpital Minjoz</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Adrien CHAUCHET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gian-Matteo Pica, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand - Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier Tournilhac, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>François LEMONNIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvain CARRAS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ch de Versailles - Hopital Andre Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline BESSON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Kamel LARIBI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Hurriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck Morschhauser, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie ABRAHAM, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yann GUILLERMIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu de Meaux</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Wajed ABARAH - ATASI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charles Herbaux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathilde LAMARQUE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nancy - Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Feugier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Steven LE GOUILL, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Morgane Cheminant, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laure Ricard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine THIEBLEMONT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie JACQUE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Kamal BOUABDALLAH, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Emmanuel BACHY, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de La Milétrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Stéphanie GUIDEZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas Daguindau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Roch HOUOT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier CAMUS, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Loïc YSEBAERT, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KIR3DL2</keyword>
  <keyword>PTCL</keyword>
  <keyword>T-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

